CDK4/6 inhibitors (CDK4/6i), such as palbociclib, ribociclib, and abemaciclib, have been approved by the FDA and have emerged as promising treatments for patients with HR + /HER2- breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.